Inogen (NASDAQ:INGN) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

Inogen, Inc (NASDAQ:INGN) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $7.03 and traded as low as $6.19. Inogen shares last traded at $6.19, with a volume of 169,003 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Inogen has a consensus rating of “Hold” and an average target price of $11.00.

Inogen Trading Down 4.8%

The business’s 50 day simple moving average is $6.06 and its two-hundred day simple moving average is $7.02. The firm has a market capitalization of $168.57 million, a PE ratio of -7.20 and a beta of 1.77.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, February 24th. The medical technology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.10. Inogen had a negative return on equity of 11.56% and a negative net margin of 6.52%.The firm had revenue of $81.72 million for the quarter, compared to the consensus estimate of $82.00 million. As a group, equities research analysts anticipate that Inogen, Inc will post -1.73 earnings per share for the current year.

Institutional Investors Weigh In On Inogen

A number of large investors have recently made changes to their positions in the company. Alliancebernstein L.P. increased its position in shares of Inogen by 3.9% during the 3rd quarter. Alliancebernstein L.P. now owns 51,120 shares of the medical technology company’s stock valued at $418,000 after purchasing an additional 1,900 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Inogen by 14.6% in the fourth quarter. Russell Investments Group Ltd. now owns 19,543 shares of the medical technology company’s stock worth $131,000 after buying an additional 2,487 shares during the last quarter. Rhumbline Advisers grew its position in Inogen by 7.0% during the second quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company’s stock valued at $275,000 after buying an additional 2,561 shares during the period. American Century Companies Inc. increased its holdings in Inogen by 4.9% during the second quarter. American Century Companies Inc. now owns 61,238 shares of the medical technology company’s stock valued at $431,000 after buying an additional 2,858 shares during the last quarter. Finally, Barclays PLC increased its holdings in Inogen by 4.5% during the fourth quarter. Barclays PLC now owns 81,980 shares of the medical technology company’s stock valued at $551,000 after buying an additional 3,515 shares during the last quarter. 89.94% of the stock is currently owned by institutional investors.

Inogen Company Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.